The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwNHL 2025 | Developing an assay for obtaining information on genetic heterogeneity in DLBCL in the community
In this video, Margaret Shipp, MD, Dana-Farber Cancer Institute, Boston, MA, briefly discusses the development of a Clinical Laboratory Improvement Amendments (CLIA)-approved assay that would capture information on the genetic heterogeneity of diffuse large B-cell lymphoma (DLBCL). This test would be widely available and accessible in the community setting, providing physicians with additional data to inform clinical decision-making and potentially improve patient outcomes. This interview took place at the 22nd International Workshop on Non-Hodgkin Lymphoma (iwNHL 2025), held in Cambridge, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
An important question also and I think one of the things that there is active work in right now is actually developing what are called CLIA-approved assays, meaning that these are assays that have met very rigorous testing criteria and are performed in clinically certified laboratories, and so the idea would be to develop the genetic test that would allow you to capture this molecular heterogeneity and have that test performed in a CLIA-certified setting...
An important question also and I think one of the things that there is active work in right now is actually developing what are called CLIA-approved assays, meaning that these are assays that have met very rigorous testing criteria and are performed in clinically certified laboratories, and so the idea would be to develop the genetic test that would allow you to capture this molecular heterogeneity and have that test performed in a CLIA-certified setting. And the reason that that would be important is then it would make that information available to actually be part of clinical decision-making for people in the community who might be interested in trying to obtain this information, capture that information, and think about what you would do with it therapeutically. So I think that probably within the next couple of years, there’s going to be a lot of work done to make these tests available in a way that would allow them to be used and broadly accessible in the community.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
